WJH-C19 is an orally active RIPK1 inhibitor with an IC50 of 5.7 nM. It suppresses the RIPK1/RIPK3/MLKL signaling pathway by blocking RIPK1 phosphorylation and inhibiting downstream phosphorylation of RIPK3 and MLKL, thereby disrupting necrosome formation and demonstrating protective effects against necroptosis (Apoptosis) across various cell lines. In a mouse model of colitis, WJH-C19 alleviates inflammatory bowel disease symptoms by modulating the necroptosis pathway. It also reduces inflammation and bone destruction in a rheumatoid arthritis mouse model. WJH-C19 is relevant for research on inflammatory bowel disease and rheumatoid arthritis.

RIPK1:5.7 nM